pharmaceutical-investing Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
pharmaceutical-investing Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX for Injection
pharmaceutical-investing Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
pharmaceutical-investing Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX for Injection
